Hematology | Phase III Developments | UNITED STATES

Akebia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia in Adult Patients on Dialysis

Lead Product(s): Vadadustat

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

In both of the two INNO2VATE trials, Vadadustat achieved primary and secondary efficacy endpoints. The cardiovascular outcomes program INNO2VATE, Phase 3 evaluates the efficacy & safety of vadadustat.

BeyondSpring

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

Lead Product(s): Plinabulin

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

If approved, Plinabulin in combination with G-CSFs can potentially be the first superior therapy to the standard of care (G-CSF alone) for chemotherapy-induced neutropenia.

Akebia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

Lead Product(s): Vadadustat

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

Details:

The posters present studies of Akebia's investigational oral HIF-prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.

Actinium pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting

Lead Product(s): Apamistamab-I-131

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

100% of patients receiving Iomab-B achieving transplant engraftment without delay compared to 18% of patients in the control arm.

BeyondSpring

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

BeyondSpring’s Plinabulin Activates Adaptive and Innate Immune System

Lead Product(s): Plinabulin

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Presentation at the 2020 ASCO-SITC provides strong validation for Plinabulin as a potent activator of the innate immune system.

Achillion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Alexion Completes Acquisition of Achillion

Lead Product(s): Danicopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

Deal Size: $930.0 million Upfront Cash: $930.0 million

Deal Type: Acquisition January 28, 2020

Details:

Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.

Dova Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia

Lead Product(s): Avatrombopag

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.

Apellis Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Apellis climbs as its drug beats Alexion's Soliris in phase 3

Lead Product(s): Pegcetacoplan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

In a head-to-head phase 3 trial after 16 weeks, hemoglobin levels in the pegcetacoplan arm had increased by 3.8 g/dL over the Soliris group, resulting in the trial hitting its primary endpoint.

Find

Find Hematology Drugs in Phase III Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Akebia Therapeutics

Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia in Adult Patients on Dialysis

BeyondSpring

BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

Akebia Therapeutics

Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

Actinium pharmaceuticals

Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting

BeyondSpring

BeyondSpring’s Plinabulin Activates Adaptive and Innate Immune System

Achillion

Alexion Completes Acquisition of Achillion

Dova Pharmaceuticals

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia

Apellis Pharmaceuticals

Apellis climbs as its drug beats Alexion's Soliris in phase 3